Attention AACR Annual Meeting 2018 Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

From Chemistry to the Clinic: Part 3 - Approaches to Drug Design for Neuro-oncology

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 5 of 5
Chair
Timothy Heffron
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2018 on April 14, 2018 3:15 PM-5:15 PM
Challenges and principles of drug design in neuro-oncology
Zoran Rankovic
St. Jude Children's Research Hospital, Memphis, TN, United States
from AACR Annual Meeting 2018 on April 14, 2018 3:15 PM-5:15 PM
Strategies in the discovery of GDC-0084: A BBB penetrating PI3K/mTOR inhibitor
Timothy Heffron
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2018 on April 14, 2018 3:15 PM-5:15 PM
Discovery of the clinical candidate AZD1390: A high quality, potent and selective inhibitor of ATM kinase with the ability to cross the blood brain barrier
Kurt G Pike
AstraZeneca, Cambridge, United Kingdom
from AACR Annual Meeting 2018 on April 14, 2018 3:15 PM-5:15 PM
Structural data in the discovery of lorlatinib and insights into mechanisms of ALK acquired resistance
Ted W. Johnson
Pfizer, Inc., San Diego, CA, United States
from AACR Annual Meeting 2018 on April 14, 2018 3:15 PM-5:15 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 5 of 5